Abstract: A comment management method manages a plurality of comments written about content and selects at least one first comment from among the plurality of comments based on a first condition that is based on feedback from users for each of the plurality of comments, selects a second comment based on the feedback and a second condition that is based on the time at which a comment is written, and distinguishably displays the first comment and the second comment on a user terminal that displays the content.

Abstract: A comment management method manages a plurality of comments written about content and selects at least one first comment from among the plurality of comments based on a first condition that is based on feedback from users for each of the plurality of comments, selects a second comment based on the feedback and a second condition that is based on the time at which a comment is written, and distinguishably displays the first comment and the second comment on a user terminal that displays the content.

Abstract: A comment management method manages a plurality of comments written about content and selects at least one first comment from among the plurality of comments based on a first condition that is based on feedback from users for each of the plurality of comments, selects a second comment based on the feedback and a second condition that is based on the time at which a comment is written, and distinguishably displays the first comment and the second comment on a user terminal that displays the content.

Abstract: A biomarker composition for diagnosing degenerative brain diseases comprises TB (TRAF-6 binding) domain in SQSTM1/p62 protein. The TB (TRAF-6 binding) domain in the SQSTM1/p62 protein directly binds to the tau protein to remove the tau protein, and thus the exposure of the TB domain may be usefully utilized in diagnosing and/or treating degenerative brain diseases in degenerative brain diseases in which tauopathy is observed.

Abstract: Provided are a composition for diagnosing Alzheimer's dementia, the composition including an agent for measuring levels of mRNAs of one or more genes selected from the group consisting of neurotrimin (NTM), peptidylglycine-?-amidating monooxygenase (PAM), receptor-type tyrosine-protein phosphatase N2 (PTPRN2), opioid-binding protein/cell adhesion molecule (OPCML), 14-3-3 protein ?/? (YWHAZ), chromogranin-A (CHGA), and secretogranin-1 (CHGB), or levels of proteins expressed therefrom; a kit for diagnosing Alzheimer's dementia, the kit including the composition; and a method of providing information for the diagnosis of Alzheimer's dementia, the method including the steps of measuring the levels of mRNAs of the genes or the levels of proteins expressed therefrom, and comparing the measured levels with those measured in a sample isolated from a normal individual.

Abstract: The present invention provides an organic light emitting device comprising a substrate, a first electrode, an organic material layer and a second electrode in sequentially laminated form, wherein a plurality of continued hemispherical recesses are formed on an upper surface of the substrate aligned adjacent to the first electrode.